AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $320.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$320.1M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 6 added, 2 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- 10+ awardsAwards on record
Key stats
Fundamentals Sep 30- Open
- $473.84
- 52-wk high
- $609.35
- High
- $486.98
- 52-wk low
- $409.07
- Low
- $470.76
- Prev close
- $481.47
- Mkt cap
- $20.65B
- P/E
- 17.2x
- Volume
- 628.3K
- Fwd P/E
- 16.4x
- Beta
- 0.56
- P/S
- 6.5x
- P/B
- 3.3x
- Profit margin
- +41.6%
- Op margin
- +42.2%
- ROE
- +19.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about UTHR filings
Are insiders buying or selling United Therapeutics Corporation (UTHR) stock?
Net selling: insiders sold $320.1M and bought $0 of UTHR stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $320M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Rothblatt, Martine A (Chairperson & CEO), who sold $298.7M. The latest filing was on Sep 30, 2026.
Which members of Congress have traded UTHR recently?
None. No member of Congress disclosed a UTHR trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this UTHR smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (2)
- MI
Millennium
$130.7M
added
- QR
Qube Research
$53.4M
added
Sells/Trims (1)
- DS
D.E. Shaw
$58.8M
sold
What insiders are doing
How top traders are positioned
No tracked top-trader positions in UTHR right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 6.6% above what analysts expected.
Earnings per share
$6.82 expected
Revenue
$804.6M expected
Reports Nov 4, 2026, in 34 days
Estimates as of Sep 30, 2026
EPS expected
$4.40 to $7.63
Revenue expected
10 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $799.5M | $790.2M | $781.5M | $783.3M |
| Cost of what it sold | $100.9M | $103.4M | $133.4M | $99.5M |
| Gross profit | $698.6M | $686.8M | $648.1M | $683.8M |
| What it spent | ||||
| Research and development | $127.5M | $139.5M | $138.2M | $146.3M |
| Sales and admin | $153.5M | $157.1M | $155.4M | $137.9M |
| Other operating costs | $28.3M | $32.7M | $28.7M | $68.8M |
| Total operating expenses | $309.3M | $329.3M | $322.3M | $353.0M |
| What was left | ||||
| Operating profit | $389.3M | $357.5M | $325.8M | $330.8M |
| Interest on debt | $3.0M | $3.1M | $3.0M | $2.9M |
| Profit before tax | $438.0M | $444.0M | $318.3M | $372.7M |
| Tax | $99.3M | $79.7M | $43.4M | $39.7M |
| Net profit | $338.7M | $364.3M | $274.9M | $333.0M |
| EBITDA | $462.9M | $469.9M | $343.9M | $375.6M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bearish
After exercising stock options, the CEO’s family trust sold 9,500 United Therapeutics (UTHR) shares.
NeutralSep 28Form 4 United Therapeutics Corporation For: 26 September By Investing.com
NeutralSep 27After exercising stock options, the CEO's family trust sold 9,500 United Therapeutics (UTHR) shares.
NeutralSep 25Why United Therapeutics (UTHR) Shares Are Falling Today
Leans bearishSep 24United Therapeutics Falls as Goldman Sachs Sets $321 Price Target
NeutralSep 24Why United Therapeutics (UTHR) Shares Are Falling Today
Leans bearishSep 24Goldman Sachs initiates United Therapeutics stock with sell rating
BearishSep 24United Therapeutics Corporation (UTHR) stock price, news, quote and history
Leans bullishSep 23
Macro
22 macro signals shaping UTHR right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results